Locally advanced vs. metastatic disease, and how uncommon each one is
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Basal cell carcinoma (BCC) is the most common cancer in the world, and for almost everyone who has one, the story ends quickly: a dermatologist removes it in a single office visit and it never returns. So it can be alarming to hear a doctor describe a BCC as "advanced."
"Advanced BCC" is not a formal stage number the way it is for some other cancers. It is a practical label doctors use for the small minority of basal cell carcinomas that can no longer be handled with routine surgery. It covers two different situations — one much more common than the other — and understanding which one applies to you shapes the entire conversation about treatment.
This page explains what each term means, how doctors decide a tumor has crossed that line, and why the label matters. For the flip side — the specific point at which surgeons and radiation oncologists step back — see when surgery and radiation are no longer enough.
When clinicians and treatment guidelines say "advanced BCC," they are grouping together two distinct problems that happen to be treated with the same systemic medications:
The tumor has grown large or deep, invaded cartilage, bone, muscle, or nerves, or come back after previous treatment — to the point where surgery or radiation can no longer remove it without unacceptable loss of function or disfigurement. It has not spread elsewhere. This accounts for the large majority of advanced cases.
The cancer has traveled beyond the skin to lymph nodes or distant organs such as the lungs, bone, or liver. This is one of the rarest events in all of oncology. It is treated with the same drugs used for locally advanced disease.
Locally advanced BCC is defined less by a single measurement and more by a judgment: could this tumor be removed with surgery, or treated with radiation, and still leave the patient with a reasonable outcome? When the honest answer is no, the tumor is considered locally advanced. Features that push a BCC into this category include:
Most people who reach this point got there over years — a tumor that was ignored, dismissed as a sore that would not heal, or treated repeatedly without changing the approach. It is uncommon, but it is also, in hindsight, usually preventable. Learn more about how BCC subtypes behave on the types of basal cell carcinoma page.
Basal cell carcinoma almost never spreads. Published estimates of how often it metastasizes vary with how the studies were done, but they cluster well below 1% of all BCCs — most figures fall between roughly 0.003% and 0.5%. For perspective, a dermatologist may treat thousands of BCCs in a career and never see one metastasize.
When it does happen, it is usually after a large, long-neglected, or repeatedly recurrent tumor on the head or neck. The most common first stop is the nearby lymph nodes; less often it reaches the lungs, bone, or liver. In the largest analysis of metastatic BCC, outcomes were meaningfully better when spread was limited to lymph nodes rather than distant organs.
Historically, metastatic BCC carried a poor prognosis. That picture has changed with the arrival of hedgehog pathway inhibitors and, more recently, immunotherapy, both of which can control the disease for extended periods.
There is no single blood test or scan that returns an "advanced" result. The determination is made by a team looking at the whole picture:
Guidelines recommend that these hard cases be reviewed by a multidisciplinary tumor board rather than decided by one clinician alone. The details of that evaluation are covered in how advanced BCC is evaluated before treatment.
The reason "locally advanced" and "metastatic" are grouped together is that once a BCC cannot be cured by cutting it out or irradiating it, the treatment strategy is the same for both: medication that circulates through the whole body.
"Advanced" basal cell carcinoma is a small corner of a very common disease. It means one of two things: a tumor that has grown or recurred beyond what surgery and radiation can fix, or — far more rarely — one that has spread beyond the skin. The first is uncommon; the second is exceptionally rare.
Either way, the diagnosis is not the dead end it once was. Systemic medications now give people with advanced BCC real, durable options, and the right next step usually begins with a team that treats these tumors regularly.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for information about advanced basal cell carcinoma
Chat with the Navigator